Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 112 citing articles:

The importance of exosomal PDL1 in tumour immune evasion
Dhouha Daassi, Kathleen M. Mahoney, Gordon J. Freeman
Nature reviews. Immunology (2020) Vol. 20, Iss. 4, pp. 209-215
Closed Access | Times Cited: 485
The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
Tang Qing, Yun Chen, Xiaojuan Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 282
Immunotherapy for hepatocellular carcinoma
Zongyi Yin, Xiaowu Li
Cancer Letters (2019) Vol. 470, pp. 8-17
Closed Access | Times Cited: 218
Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
Mengke Niu, Yiming Liu, Ming Yi, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 92
Immunotherapy for hepatocellular carcinoma: Recent advances and future targets
Su Jong Yu
Pharmacology & Therapeutics (2023) Vol. 244, pp. 108387-108387
Closed Access | Times Cited: 42
Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance
Manshi Yang, Mengying Cui, Yang Sun, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 17
Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy
Muhammad Khan, Zhihong Zhao, Sumbal Arooj, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 131
Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association With Vascular Formation
Shinji Itoh, Tomoharu Yoshizumi, Kyohei Yugawa, et al.
Hepatology (2020) Vol. 72, Iss. 6, pp. 1987-1999
Closed Access | Times Cited: 100
Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy
Muhammad Saleem Iqbal Khan, Sumbal Arooj, Hua Wang
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 77
Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies
Kaijian Zhou, Shu Guo, Fei Li, et al.
Frontiers in Cell and Developmental Biology (2020) Vol. 8
Open Access | Times Cited: 76
The Immunology of Hepatocellular Carcinoma
Gbemisola Lawal, Yao Xiao, Amir A. Rahnemai‐Azar, et al.
Vaccines (2021) Vol. 9, Iss. 10, pp. 1184-1184
Open Access | Times Cited: 63
Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies
Stephanie Pitts, Jeffrey Schlom, Renee N. Donahue
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 8
Emerging biomarkers in HCC patients: Current status
Hugo P. Marques, Sílvia Silva, Eléonora De Martin, et al.
International Journal of Surgery (2020) Vol. 82, pp. 70-76
Closed Access | Times Cited: 60
Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors
Kiyohiro Ando, Kazuyuki Hamada, Makoto Watanabe, et al.
Anticancer Research (2019) Vol. 39, Iss. 9, pp. 5195-5201
Open Access | Times Cited: 57
Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma
Minh Phuong Dong, Masaru Enomoto, Lê Thị Thanh Thủy, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 55
Soluble programmed death-ligand 1 rather than PD-L1 on tumor cells effectively predicts metastasis and prognosis in soft tissue sarcomas
Kunihiro Asanuma, Tomoki Nakamura, Akinobu Hayashi, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 48
Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis
Xiaosong Li, Junwei Li, Hui Li, et al.
Bioscience Reports (2020) Vol. 40, Iss. 4
Open Access | Times Cited: 46
Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients
Yusuke Omura, Yuji Toiyama, Yoshinaga Okugawa, et al.
Cancer Immunology Immunotherapy (2020) Vol. 69, Iss. 12, pp. 2533-2546
Open Access | Times Cited: 45
The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte
Baojuan Han, Lina Dong, Jing Zhou, et al.
Cancer Immunology Immunotherapy (2021) Vol. 70, Iss. 10, pp. 2893-2909
Open Access | Times Cited: 37
Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer
Yinjun He, Xiang Zhang, Ming Zhu, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 16
Recent Advancement of PD-L1 Detection Technologies and Clinical Applications in the Era of Precision Cancer Therapy
Yuanfeng Zhang, Juanjuan Wu, Chaobin Zhao, et al.
Journal of Cancer (2023) Vol. 14, Iss. 5, pp. 850-873
Open Access | Times Cited: 16
Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma
Jun Ho Ji, Sang Yun Ha, Danbi Lee, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 8, pp. 7640-7640
Open Access | Times Cited: 14
Soluble programmed death ligand‐1‐induced immunosuppressive effects on chimeric antigen receptor‐natural killer cells targeting Glypican‐3 in hepatocellular carcinoma
Lin Chen, Siyuan Liu, Dickson Adah, et al.
Immunology (2023) Vol. 169, Iss. 2, pp. 204-218
Open Access | Times Cited: 13
Clinical significance of serum-derived exosomal PD-L1 expression in patients with advanced pancreatic cancer
Se Jun Park, Ju Yeon Park, Kabsoo Shin, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 13
Interferon‑γ induced PD‑L1 expression and soluble PD‑L1 production in gastric cancer
Yushi Imai, Tetsuhiro Chiba, Takayuki Kondo, et al.
Oncology Letters (2020) Vol. 20, Iss. 3, pp. 2161-2168
Open Access | Times Cited: 39
Page 1 - Next Page

Scroll to top